Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

NCT06321341 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Vertigo
Autonomic Dysfunction

Interventions

DRUG: Vespireit
DRUG: Arlevert

Sponsor

Valenta Pharm JSC